🇺🇸 FDA
Patent

US 7563585

Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)

granted A61KA61K38/00

Quick answer

US patent 7563585 (Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jul 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00